Skip to main content
Photo header of senior man
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE®

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior man header
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Syn-One Test named a top 2024 medical innovation by NIH. 40,000+ patients tested with Syn-One – and counting.

Introducing the Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
August 12, 2025

Beyond P-SYN: Why CND Evaluates Skin Histology

When CND Life Sciences launched the Syn-One Test®, we anticipated that the pathological information gained…
Insights
July 14, 2025

CND Becomes an Educational Sponsor of the Proactive Brain Health Alliance

CND Life Sciences understands the need for education, support, and advocacy for those who are…
Insights
July 1, 2025

Lead Investigator Discusses the Impact of the Syn-One Test® Clinical Utility Study

Parkinson’s disease and related disorders such as dementia with Lewy bodies and multiple system atrophy…
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

News Release
November 6, 2025

Using Skin Biopsy Technology, CND Life Sciences Performs the 50,000th Syn-One Test® for Patients

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests…
On Our Radar
October 28, 2025

New Study Evaluates Skin Biopsy Testing in Patients With Recent-Onset Cognitive Decline

A new study published in Annals of Clinical and Translational Neurology examined the use of…
News Release
October 22, 2025

CND Life Sciences Announces NIH Grant to Study the Risk of Parkinson’s Disease in Patients with Essential Tremor

The grant will fund a three-year multicenter study performed in collaboration with major medical centers…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our Skin Biopsy Test Kit, collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit